September 4, 2018
Collaboration between University of Pennsylvania and Precision Biosciences to Develop Genome Editing Therapeutics
DURHAM, North Carolina, USA, September 04, 2018 – Precision BioSciences today announced an expansion of their ongoing collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania (Penn) to pursue research and development of gene editing therapies. This relationship will allow Precision and Penn to design new in vivo gene therapies based on Precision’s proprietary ARCUS genome editing technology.
Precision Biosciences founded in 2006 by Duke Inventors Drs. Derek Jantz and James Smith utilize a proprietary genome editing method called ARCUS. Genome editing technologies allow a rethinking approach to a broad array of serious challenges faced by the world today. CSO Derek Jantz stated, “We are excited to expand our collaboration with Jim Wilson and the Penn Gene Therapy Program. The Wilson laboratory is unparalleled in its ability to translate cutting-edge gene therapy technology into potential treatments for patients in need. The team’s proven success identifying gene therapy candidates and advancing them through preclinical development allows them to provide the critical insight needed to help move ARCUS into the clinic.”